On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with ...
Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...
Eczema is a common skin condition that causes itchiness, burning and dryness. Dry skin occurs when your skin loses too much ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study ...
Adults with atopic eczema are significantly more likely to experience suicidal thoughts than those without the skin condition ...
Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...
A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...
Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback